Form 4: Director Mark Davis Receives Myriad Genetics Equity Grant

Director Mark Steven Davis was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Summary

• Director Mark Steven Davis acquired 59,701 restricted stock units (RSUs) on June 4, 2026.
• The grant was issued under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• The total beneficial ownership for the director following this transaction is 106,665 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and issuance of the underlying common stock.

Risks

• Vesting is subject to the passage of time or the occurrence of the next annual meeting, which may be impacted by corporate governance or operational changes.

Future Outlook

The RSUs vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward company performance.

Comparison to Industry Standards

• The use of RSU-based compensation for board members is consistent with standard practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common in the industry to align director tenure with shareholder cycles.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of the 59,701 RSUs on the earlier of June 4, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation